Skip to content Skip to footer
Subscribe Now
NEWS

Eli Lilly to Acquire Centessa Pharmaceuticals in a Deal Valued at ~$7.8B

Shots: Eli Lilly has entered into a definitive agreement to acquire Centessa Pharmaceuticals incl. its asset cleminorexton & ORX142, expanding Lilly's neuroscience portfolio & capabilities into sleep medicine As per the deal, Lilly will acquire all issued & to-be-issued share capital of Centessa (incl. ADSs) for $38/share in cash (~$6.3B upfront), plus a non-transferable CVR of…
March 31, 2026

Read more

NEWS

Insilico Medicine and Eli Lilly Sign ~$2.75B Multi-Program AI-Driven Drug Discovery Collaboration

Shots: Insilico has entered into a drug discovery collaboration with Eli Lilly to accelerate the discovery & development of novel therapeutics across multiple therapeutic areas using Insilico’s Pharma.AI As per the deal, Lilly will gain exclusive global rights to develop, manufacture & commercialize Insilico’s preclinical oral candidates for select indications. Also, both will collaborate on…
March 30, 2026

Read more

TOP 20

Top 20 Life Sciences Deals of 2025 

Shots:  From AI-powered discovery to next-generation biologics and gene editing, 2025 was a blockbuster year for life sciences dealmaking. Pharma and biotech companies signed multibillion-dollar partnerships and acquisitions to accelerate innovation across oncology, cardiometabolic diseases, neurology, and rare disorders.  Platform technologies dominated the deal landscape, with big pharma securing access to cutting-edge modalities from bispecific…
March 20, 2026

Read more

Eli lilly
NEWS

Eli Lilly Reports the P-IIIb (TOGETHER-PsO) Trial Data on Taltz + Zepbound for Adults with Psoriasis and Obesity or Overweight

Shots: Eli Lilly has reported P-IIIb (TOGETHER-PsO) trial data assessing Taltz (ixekizumab) + Zepbound (tirzepatide) vs Taltz alone in 274 adults with mod. to sev. plaque psoriasis & obesity/overweight with ≥1 additional weight-related comorbid condition At 36wks., the trial met its 1EP with 27.1% pts reaching PASI 100 & ≥10% weight loss compared to 5.8% pts. Trial…
February 19, 2026

Read more

Eli lilly
NEWS

Eli Lilly Reports P-III (LIBRETTO-432) Trial Findings on Retevmo (Selpercatinib) in RET Fusion-Positive NSCLC

Shots: Eli Lilly has reported P-III (LIBRETTO-432) trial data assessing Retevmo vs PBO in 151 pts with RET fusion-positive NSCLC following completion of definitive radiotherapy or surgery with curative intent, & other adjuvant therapy, if indicated Trial met its 1EP, showing improvement in investigator-assessed EFS in early-stage (II-IIIA) pts, plus OS data was immature but demonstrated a…
February 17, 2026

Read more

NEWS

Eli Lilly to Acquire Orna Therapeutics for ~$2.4B

Shots: Eli Lilly has entered into a definitive agreement to acquire Orna Therapeutics, gaining a broad platform to drive long-term innovation in genetic medicine & in vivo cell engineering As per the deal, Lilly will acquire Orna, with Orna’s shareholders receiving up to $2.4B in cash, incl. an upfront & subsequent clinical development milestones payment Acquisition…
February 10, 2026

Read more

NEWS

Innovent and Eli Lilly Strike ~$8.85B ex-China Collaboration to Accelerate Oncology & Immunology Programs

Shots: Innovent & Eli Lilly have entered into a strategic collaboration to advance novel medicines in oncology & immunology As per the deal, Innovent will advance the programs from discovery through P-II PoC trial in China using its antibody platforms, while Lilly will receive exclusive rights to develop & commercialize the assets globally, excl. Greater…
February 9, 2026

Read more

Load more